MP19-06 OVERALL, SPECIFIC, AND METASTASIS-FREE SURVIVAL OF AFRO-CARIBBEAN MEN WITH PATHOLOGICAL GLEASON 6 PROSTATE CANCER.

Abstract

You have accessJournal of UrologyProstate Cancer: Localized: Surgical Therapy I (MP19)1 Apr 2020MP19-06 OVERALL, SPECIFIC, AND METASTASIS-FREE SURVIVAL OF AFRO-CARIBBEAN MEN WITH PATHOLOGICAL GLEASON 6 PROSTATE CANCER. Philippe Mollard, Emmanuel Perrot, Pascal Blanchet, and Laurent Brureau* Philippe MollardPhilippe Mollard More articles by this author , Emmanuel PerrotEmmanuel Perrot More articles by this author , Pascal BlanchetPascal Blanchet More articles by this author , and Laurent Brureau*Laurent Brureau* More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000000852.06AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Several studies in the Caucasian population have shown that patients with Gleason 6 prostate cancer, based on surgical specimens, have low or no risk of metastasis. However, there is no data for men of African ancestry. The objective of this study was to estimate the overall, specific, and metastasis-free survival of patients with a Gleason 6 score, based on the surgical specimen. METHODS: This was a monocentric retrospective study that included 723 consecutive patients treated by radical prostatectomy between January 1, 2000 and March 31, 2018, with a Gleason score of 6 based on the surgical specimen. Specific survival was defined as the time elapsed between surgery and death attributed to prostate cancer. Overall survival was defined as the time elapsed between surgery and death from all causes. The causes of death were verified in the medical records. Survival analyses without biological recurrence and without salvage treatment were performed according to the Kaplan-Meier method. The Cox model was used for univariate and multivariate analyses. RESULTS: In total, 691 patients were included because 32 were excluded for missing data. Overall five- and ten-year survival were 94.2% and 87.1%, respectively. Specific survival and metastasis-free survival were 100%, with a median follow-up of 8.5 years. The biochemical recurrence rate was 16.5%, with a median time to biochemical recurrence of 5.1 years. The frequency of salvage treatment was13.0%, with a median time to surgery of 7.3 years. In univariate analysis, PSA, pathological stage, seminal vesicle invasion, positive margins, and lymph node dissection were significantly associated with an increased risk of biochemical recurrence and salvage treatment, but only PSA and positive margins were significantly associated by multivariate analysis. CONCLUSIONS: No metastasis or disease-specific deaths were observed for men with Gleason score ≤ 6 prostate cancer at radical prostatectomy, in particular, men of African ancestry. Source of Funding: None © 2020 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 203Issue Supplement 4April 2020Page: e300-e300 Advertisement Copyright & Permissions© 2020 by American Urological Association Education and Research, Inc.MetricsAuthor Information Philippe Mollard More articles by this author Emmanuel Perrot More articles by this author Pascal Blanchet More articles by this author Laurent Brureau* More articles by this author Expand All Advertisement PDF downloadLoading ...